OBR Daily Commentary

forumImage

FDA Head Walks Back Claim of Dramatic Benefit From Covid Therapy

(Bloomberg) Aug 24, 2020 - The head of the U.S. Food and Drug Administration walked back his claim that an experimental therapy had provided a dramatic benefit to Covid-19 patients, a rare reversal for an agency that has prided itself on rock-solid science and public trust.

Read Article arrow

Dean Gesme, MD (Posted: August 25, 2020)

quotesDr Hahn’s public misstatement and obvious exaggeration of what is known concerning plasma therapy for Covid is careless at best or politically-calculated at worse. Entirely unacceptable from an agency upon whose future the world looks for innovations and enhancements in drug therapies for serious disease.quotes

Add Comment 1 Comment
forumImage

Trump Expected To Sign Drug Pricing Executive Orders Friday, Angering Pharma

(Washington Post) July 24, 2020 - President Trump is expected to sign three health care executive orders on Friday — two of which target the pharmaceutical industry on drug pricing — even as the administration depends on it to develop vaccines to help end the coronavirus pandemic.

Read Article arrow

Dean Gesme, MD (Posted: July 26, 2020)

quotesTrump gave just Congress and manufacturers 30 days to develop and pass a Part B Medicare drug acquisition Bill. If not accomplished, then Trump’s Executive order of July 24, 2020 will implement CMS’ International Pricing Index to slash Part B drug prices. Highly disruptive to oncology providers of care!quotes

Add Comment 1 Comment
forumImage

Lilly Surges On Verzenio Survival Data In Early Breast Cancer

(PMLiVE [UK]) June 17, 2020 - New data with Eli Lilly’s CDK4/6 inhibitor Verzenio has sent the drug to the top of the class in patients with hormone receptor-positive, HER2-negative early-stage breast cancer.

Read Article arrow

Dean Gesme, MD (Posted: June 18, 2020)

quotesThe positive primary endpoint of improved iDFS with Abemaciclib plus adjuvant AI in this Monarch E interim evaluation stands in confusingly stark contrast to the negative efficacy reported from the preliminary PALLUS for adjuvant high risk early stage breast cancer! Could this be due to genuine differences in efficacy, differences in the study populations, or just statistical flukes in the data?quotes

Add Comment 1 Comment

Meet the Editorial Board

Prostate Cancer
member photo
Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical O...

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Associate Clinical Professor, Medical Oncology Executi...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Woo...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics Professo...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Steven Spielberg Family Chair in Hematology Oncology P...

member photo
Stephen M. Schleicher, M.D., MBA

Community Oncology, Medical Oncologist, OneOncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...